HER2 Positive Breast Cancer

HER2 Positive Breast Cancer : Reviewing Abstracts Published by Authors S. Loibl, Carsten Denkert & Oleg Gluz

Speaker :

Dr. Rakesh Reddy, Medical Oncologist, Hyderabad

Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with  residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Sub group analysis from KATHERINE

Author: S. Loibl 

Citation: Annals of Oncology (2020) 31 (suppl_2): S48-S53

Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab  emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease  after neoadjuvant therapy for HER2-positive breast cancer

Author: Carsten Denkert 

Citation: ASCO 2020 Abstract 502 

De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab  for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant  WSG-TP-II study

Author: Oleg Gluz

Citation: J Clin Oncol 38: 2020 (suppl; ASCO abstr 515)